查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1831001

特发性肺纤维化治疗市场

Idiopathic Pulmonary Fibrosis Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

特发性肺纤维化治疗市场预计将从 2024 年的 65.6 亿美元成长到 2031 年的 141 亿美元，2025 年至 2031 年期间的复合年增长率预计为 12.0%。

分析师观点：特发性肺纤维化是一种慢性疾病，会影响肺泡周围的组织。由于不明原因，肺组织变得僵硬增厚，随着时间的推移会形成永久性瘢痕，影响患者的呼吸。目前，特发性肺纤维化尚无根治方法。肺部復健、药物治疗和手术等治疗方法旨在减缓肺部损伤并改善患者的生活品质。

特发性肺纤维化发生率的上升，加上吸烟人数的增加，推动了未来几年对有效治疗方案的需求。旨在开发特发性肺纤维化有效药物的持续研究预计将在未来进一步促进市场成长。此外，已开发市场和新兴市场的医疗保健支出都在成长，这可能会激励製造商专注于开发新的创新产品。

市场概览：纤维化是指结缔组织的积聚，可作为正常癒合过程的一部分发生，也可作为病理状态发生。特发性肺纤维化具体影响肺部和肺泡（肺泡）内的结缔组织。这种疾病会导致健康人在日常非剧烈活动中出现呼吸困难。特发性肺纤维化治疗市场的扩张与纤维化疾病盛行率的上升和吸烟率的上升有关。研发的快速进步预计将在不久的将来为特发性肺纤维化治疗市场创造成长机会。

战略洞察

市场驱动力：特发性肺纤维化发生率上升推动市场成长

根据美国肺臟协会2022年11月更新的资料，美国每年约有5万例特发性肺纤维化新病例。此病症状在50至70岁的人群中更为明显。 2022年9月发表在《英国医学杂誌》上的一篇文章指出，2021年专科护理单位中特发性肺纤维化的估计盛行率为每10万人36.0例。由于老化、肥胖、高血压和家族史等常见风险因素，全球特发性肺纤维化患者数量正在上升，这给社会经济带来了沉重的负担。因此，特发性肺纤维化患者人数的增加支持了纤维化疾病治疗市场的成长。

細項分析：特发性肺纤维化治疗市场依药物类型分为尼达尼布、吡非尼酮和其他药物。尼达尼布在2022年占据了较大的市场份额，而其他药物预计在2022年至2030年期间的复合年增长率将达到46.3%。吡非尼酮和尼达尼布是治疗纤维化疾病最常用的处方药。

区域分析：北美引领全球特发性肺纤维化治疗市场，2022 年价值 23.6295 亿美元，预计到 2030 年将达到 55.2728 亿美元，2022-2030 年期间的预计复合年增长率为 11.2%。北美市场分为美国、加拿大和墨西哥。特发性肺纤维化发生率的上升和治疗技术的进步有利于北美市场。主要参与者的产品发布和策略倡议也促进了市场成长。随着旨在治疗特发性肺纤维化的研发活动的增加，改进的药物正在被引入，从而提高了更广泛患者群体获得治疗的机会。此外，该地区广泛的 FDA 批准鼓励公司推出技术先进的产品。

欧洲特发性肺纤维化盛行率不断上升，医疗支出也居高不下，在全球纤维化疾病治疗市场中占第二大份额。由于德国更容易获得先进的医疗产品和服务，预计将引领欧洲特发性肺纤维化治疗市场。

预计2022年至2030年，亚太地区将在全球特发性肺纤维化治疗市场中呈现最快的复合年增长率。这项预期成长得益于创新技术的广泛应用，这些技术能够在显着缩短的时间内提供准确的结果。该地区的医疗保健产业正在利用人工智慧、自动化和数位转型方面的进步，提高医务人员的效率和生产力。各行各业的持续转型增强了亚太地区的企业和经济实力，使其成为一个快速发展的枢纽，并以充满活力和前瞻性的方式实现永续发展。

关键参与者分析：特发性肺纤维化治疗市场的分析包括 Genentech, Inc. 和 Boehringer Ingelheim International GmbH 等关键参与者。

特发性肺纤维化治疗市场报告范围

最新动态：特发性肺纤维化治疗市场的公司正在积极推行无机和有机策略，例如併购。一些最新动态包括：

2023年5月，勃林格殷格翰启动了新型IL-11抑制剂抗体BI 765423的临床开发。 1期临床研究（NCT05658107）旨在评估其在健康志愿者中的安全性、耐受性和药物动力学。临床前研究表明，该抗IL-11药物在抑制并可能逆转各种纤维化疾病的纤维化方面具有良好的效果。

2022年10月，勃林格殷格翰在FIBRONEER-IPF III期临床试验中招募了首位美国患者，该试验旨在评估BI 1015550。 BI 1015550是一种实验性磷酸二酯酶4B (PDE4B) 抑制剂，旨在治疗特发性肺纤维化患者。该研究是全球FIBRONEER计画的一部分，该计画包含两项III期临床试验：针对特发性肺纤维化患者的FIBRONEER-IPF和针对其他进行性纤维化间质性肺疾病(ILD)成人患者的FIBRONEER-ILD。

2022 年 9 月，Bellerophon Therapeutics, Inc. 宣布 FDA 接受了其减少正在进行的 INOpulse REBUILD 3 期註册试验规模的申请，该试验用于治疗纤维化间质性肺病 (LD)。

2022年5月，药物安全解决方案领导者ArisGlobal收购了勃林格殷格翰旗下的BRASS数位创新技术。此次收购使ArisGlobal能够透过将BRASS整合到LifeSphere Clarity中来增强其LifeSphere技术平台，从而提升整个行业的药物警戒和患者安全。此外，ArisGlobal也扩大了其临床诊断业务的全球影响力，巩固了其市场地位。

2022年3月，百时美施贵宝宣布透过最终合併协议以每股76.00美元收购Turning Point Therapeutics, Inc.。此次收购显着增强了百时美施贵宝在全球医药市场的影响力，使其能够更积极主动地进行创新，同时扩大其救命疗法和治疗方案组合。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：特发性肺纤维化治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：特发性肺纤维化治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：特发性肺纤维化治疗市场-全球市场分析

  • 特发性肺纤维化治疗－全球市场概览
  • 特发性肺纤维化治疗－全球市场及2030年预测

第七章：特发性肺纤维化治疗市场-收入分析-按药物类型，2020-2030

  • 概述
  • 尼达尼布
  • 吡非尼酮
  • 其他的

第 8 章：特发性肺纤维化治疗市场 - 收入分析 - 按最终用户，2020-2030 年

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第九章：特发性肺纤维化治疗市场-收入分析，2020-2030-地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 12 章：特发性肺纤维化治疗市场 - 主要公司简介

  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb
  • Shionogi and Co. Ltd.
  • Cipla Ltd
  • Others

第 13 章：附录

简介目录
Product Code: TIPRE00005557

The market for idiopathic pulmonary fibrosis treatment is anticipated to grow from US$ 6.56 billion in 2024 to US$ 14.10 billion by 2031, with an estimated CAGR of 12.0% during the period from 2025 to 2031.

Analyst Perspective:Idiopathic pulmonary fibrosis is a chronic disease that impacts the tissue surrounding the alveoli in the lungs. It occurs when lung tissues become stiff and thick for unknown reasons, leading to permanent scarring over time, which complicates breathing for patients. At present, there is no definitive cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medications, and surgical options aim to slow lung damage and improve the quality of life for patients.

The rising incidence of idiopathic pulmonary fibrosis, coupled with an increasing number of smokers, is driving the demand for effective treatment options in the upcoming years. Ongoing research aimed at developing effective drugs for idiopathic pulmonary fibrosis is expected to further enhance market growth in the future. Additionally, healthcare spending is on the rise in both developed and emerging markets, which is likely to motivate manufacturers to focus on creating new and innovative products.

Market Overview:Fibrosis refers to the accumulation of connective tissue that can occur as part of the normal healing process or as a pathological condition. Idiopathic pulmonary fibrosis specifically affects the connective tissue in the lungs and alveoli (the air sacs in the lungs). This condition can lead to shortness of breath during routine activities that are not strenuous for healthy individuals. The expansion of the idiopathic pulmonary fibrosis treatment market is linked to the increasing prevalence of fibrotic conditions and a rise in smoking rates. Rapid advancements in research and development are expected to create growth opportunities for the idiopathic pulmonary fibrosis treatment market in the near future.

Strategic Insights

Market Driver:Increasing Incidence of Idiopathic Pulmonary Fibrosis Fuels Market Growth

As per the American Lung Association's data updated in November 2022, around 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed annually in the US. Symptoms of this condition are more pronounced in individuals aged 50 to 70. An article published in the British Medical Journal in September 2022 indicated that the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is rising globally due to common risk factors such as aging, obesity, hypertension, and family history, making it a significant socioeconomic burden. Consequently, the increasing patient population with idiopathic pulmonary fibrosis supports the growth of the fibrotic disease treatment market.

Segmental Analysis:The idiopathic pulmonary fibrosis treatment market is categorized by drug type into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022, while the others segment is projected to achieve a higher CAGR of 46.3% from 2022 to 2030. Pirfenidone and nintedanib are the most commonly prescribed medications for treating fibrotic diseases.

Regional Analysis:North America leads the global idiopathic pulmonary fibrosis treatment market, valued at US$ 2,362.95 million in 2022 and expected to reach US$ 5,527.28 million by 2030, with a projected CAGR of 11.2% during 2022-2030. The North American market is divided into the US, Canada, and Mexico. The increasing incidence of idiopathic pulmonary fibrosis and advancements in treatment technologies are beneficial for the market in North America. Product launches and strategic initiatives by key players also contribute to market growth. With the rise in research and development activities aimed at treating idiopathic pulmonary fibrosis, improved medications are being introduced, enhancing access to treatments for a broader patient base. Furthermore, extensive FDA approvals in the region encourage companies to launch technologically advanced products.

Europe, with its rising prevalence of idiopathic pulmonary fibrosis and high healthcare spending, holds the second-largest share in the global fibrotic disease treatment market. Germany is expected to lead the European idiopathic pulmonary fibrosis treatment market due to better access to advanced healthcare products and services.

The Asia Pacific region is anticipated to exhibit the fastest CAGR in the global idiopathic pulmonary fibrosis treatment market from 2022 to 2030. This projected growth is attributed to the widespread adoption of innovative technologies that yield accurate results in a significantly shorter timeframe. Healthcare sectors across the region are leveraging advancements in artificial intelligence, automation, and digital transformation, enhancing efficiency and productivity among medical professionals. The ongoing transformation across various industries strengthens businesses and economies in the Asia Pacific, positioning them as a rapidly developing hub with a dynamic and forward-thinking approach to sustainable growth.

Key Player Analysis:The analysis of the idiopathic pulmonary fibrosis treatment market includes key players such as Genentech, Inc. and Boehringer Ingelheim International GmbH.

Idiopathic Pulmonary Fibrosis Treatment Market Report Scope

Recent Developments:Companies in the idiopathic pulmonary fibrosis treatment market are actively pursuing both inorganic and organic strategies, such as mergers and acquisitions. Some recent developments include:

In May 2023, Boehringer Ingelheim began clinical development of BI 765423, a novel IL-11 inhibitor antibody. The Phase 1 study (NCT05658107) aims to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. Preclinical studies have shown promising results for this anti-IL-11 drug in inhibiting and potentially reversing fibrosis in various fibrotic conditions.

In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550, an experimental phosphodiesterase 4B (PDE4B) inhibitor designed for treating individuals with idiopathic pulmonary fibrosis. This study is part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF for idiopathic pulmonary fibrosis patients and FIBRONEER-ILD for adults with other progressive fibrosing interstitial lung diseases (ILDs).

In September 2022, Bellerophon Therapeutics, Inc. announced that the FDA accepted its application for reducing the trial size for the ongoing REBUILD Phase 3 registration trial of INOpulse, indicated for the treatment of fibrotic interstitial lung disease (LD).

In May 2022, ArisGlobal, a leader in drug safety solutions, acquired Boehringer Ingelheim's BRASS digital innovation. This acquisition allowed ArisGlobal to enhance its LifeSphere technology platform by integrating BRASS into LifeSphere Clarity, advancing pharmacovigilance and patient safety across the industry. Additionally, ArisGlobal has expanded its clinical diagnostics business presence globally, strengthening its position.

In March 2022, Bristol Myers Squibb announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition significantly bolstered Bristol Myers Squibb's global presence in the pharmaceutical market, enabling it to be more proactive in delivering innovations while expanding its portfolio of life-saving therapies and treatments.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Idiopathic Pulmonary Fibrosis Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Idiopathic Pulmonary Fibrosis Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Idiopathic Pulmonary Fibrosis Treatment Market - Global Market Analysis

  • 6.1 Idiopathic Pulmonary Fibrosis Treatment - Global Market Overview
  • 6.2 Idiopathic Pulmonary Fibrosis Treatment - Global Market and Forecast to 2030

7. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

  • 7.1 Overview
  • 7.2 Nintedanib
  • 7.3 Pirfenidone
  • 7.4 Others

8. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
    • 9.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts to 2030
    • 9.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
    • 9.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
        • 9.1.5.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
        • 9.1.5.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market, by End User
      • 9.1.5.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
        • 9.1.5.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
        • 9.1.5.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by End User
      • 9.1.5.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
        • 9.1.5.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
        • 9.1.5.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by End User
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Idiopathic Pulmonary Fibrosis Treatment Market - Key Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Boehringer Ingelheim
  • 12.3 AstraZeneca
  • 12.4 Bristol Myers Squibb
  • 12.5 Shionogi and Co. Ltd.
  • 12.6 Cipla Ltd
  • 12.7 Others

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud